A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2018
At a glance
- Drugs Folinic acid (Primary) ; Pralatrexate (Primary)
- Indications Cutaneous T cell lymphoma; Haematological malignancies; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.